Plasma-Based, Tumour-Informed MRD Analysis May Predict Recurrence During Adjuvant Osimertinib and Follow-Up in Resected, EGFR-mutated NSCLC By Ogkologos - April 2, 2025 785 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an exploratory analysis of the ADAURA study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR FDA Grants Accelerated Approval to Loncastuximab Tesirine-lpyl for Large B-Cell Lymphoma April 29, 2021 Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary... August 10, 2026 Low Risk of Cardiotoxicity with Immune Checkpoint Inhibitor Monotherapy or Combination... December 9, 2020 Jimmy Carter Signed This Treaty Demanding An End To Violence Against... May 7, 2021 Load more HOT NEWS Vepdegestrant Prolongs PFS in a Subgroup of Patients with ER-positive, HER2-negative... 5-Yr-Old Has Cutest Celebration With Big Brother After Being Declared Cancer-Free. For Childhood Eye Cancer, Researchers Investigating “Packaged” CAR T Cells Discovery of Tumor Suppressor Suggests New Cancer Treatment Strategies
